Seres Therapeutics, Inc. (MCRB) Free cash flow 2016–2025
Seres Therapeutics, Inc. (MCRB) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
$865,000FY2025 · since FY2016: $22.4M → $865,000
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $865,000 | +100.6% |
| FY2024 | -$149.0M | -18.9% |
| FY2023 | -$125.3M | +47.5% |
| FY2022 | -$238.6M | -8191.8% |
| FY2021 | -$2.9M | +96.9% |
| FY2020 | -$94.2M | -21.5% |
| FY2019 | -$77.5M | -19.6% |
| FY2018 | -$64.8M | +19.2% |
| FY2017 | -$80.2M | -457.6% |
| FY2016 | $22.4M | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice
More MCRB financial trends
MCRB RevenueMCRB Net incomeMCRB Net marginMCRB Gross profitMCRB Gross marginMCRB Operating incomeMCRB Operating marginMCRB Operating cash flowMCRB Capital expendituresMCRB Return on equityMCRB Stock buybacksMCRB Dividends paidMCRB Total assetsMCRB Total liabilitiesMCRB Shareholders’ equityMCRB overview →